Page last updated: 2024-11-13

kgp94

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

KGP94: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25234575
SCHEMBL ID6337731
MeSH IDM0584793

Synonyms (11)

Synonym
[(e)-[(3-bromophenyl)(3-hydroxyphenyl)methylidene]amino]thiourea
kgp94
gtpl6533
SCHEMBL6337731
HY-118762
MS-25407
1131456-28-4
kgp 94
kgp-94
CS-0068464
[(z)-[(3-bromophenyl)-(3-hydroxyphenyl)methylidene]amino]thiourea

Research Excerpts

Overview

KGP94 is a potent, selective, and competitive inhibitor of the lysosomal endopeptidase enzyme (Cathepsin L) Currently in preclinical trials for the treatment of metastatic cancer.

ExcerptReferenceRelevance
"KGP94 is a potent, selective, and competitive inhibitor of the lysosomal endopeptidase enzyme (Cathepsin L) currently in preclinical trials for the treatment of metastatic cancer, which is a leading cause of cancer-associated death. "( An efficient and concise synthesis of a selective small molecule non-peptide inhibitor of cathepsin L: KGP94.
Munikishore, R; Wang, LL; Zhang, S; Zhao, QS; Zuo, Z, 2021
)
2.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]